Anti-obesity drugs 'fail to reduce weight'

Anti-obesity drugs are unlikely to permanently reduce patients’ weight, Canadian research findings suggests.

A meta-analysis showed little evidence that orlistat, sibutramine or rimonabant reduced patients’ weight loss by 5 per cent.

Such ‘modest’ weight loss could mean many patients will remain significantly overweight or obese despite drug treatment, say the researchers.

The study focused on 30 randomised placebo-controlled studies into anti-obesity drugs, involving almost 20,000 patients treated for at least one year.

Analysis showed that compared with placebo, orlistat reduced weight by an average of 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. As the average starting weight of participants was 100kg, the drugs often failed to reduce body weight by 5 per cent.

Of note, 30-40 per cent of participants dropped out of the trials, potentially affecting perceived effectiveness of the drug.

Last December, NICE published public health guidance on obesity. Use of orlistat and sibutramine were recommended if patients with a BMI of 30 or more fail to respond to lifestyle interventions.

However, treatment should only be continued beyond six months if the patient manages to lose 5 per cent body weight in that time, according to NICE.

NICE is also carrying out a technology appraisal into rimonabant, which was licensed by the EMEA last June.

rachel.liddle@haymarket.com

Visit the BMJ website

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

The healthcare crisis in Myanmar - how UK GPs can help

The healthcare crisis in Myanmar - how UK GPs can help

Dr Jim Brockbank from Myanmar UK GP Health Action provides an update on how the military...

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

More than four fifths of GPs say e-consultation systems adopted in the pandemic have...

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Tens of millions of COVID-19 jabs have been administered across England, but how...

Podcast: Greener practice, sharing patient data and additional roles

Podcast: Greener practice, sharing patient data and additional roles

In this episode we look at data extraction from GP records, ask whether the additional...

Red flag symptoms: Loss of consciousness

Red flag symptoms: Loss of consciousness

Red flag symptoms to look out for in presentations of loss of consciousness, including...

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

NHS England has announced £20m in funding to help local COVID-19 vaccination sites...